CEO Steven Paul was paid $11,224,103 in fiscal year 2022, ↓ down 14.6% from fiscal year 2021, the 69th percentile of its disclosed peer group (SEC filing 0000950170-23-014979 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$11,224,103 ↓ Steven Paul total, FY2022 | 69th CEO pay percentile vs peers | 27:1 CEO-to-median pay ratio | 65.16% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steven Paul | $700,000 | $0 | $0 | $9,905,953 | $609,000 | $0 | $9,150 | $11,224,103 |
| President and Chief Executive Officer | ||||||||
| Andrew Miller | 500,000 | 0 | 0 | 4,939,490 | 326,250 | 0 | 9,150 | 5,774,890 |
| Chief Operating Officer | ||||||||
| Stephen Brannan | 470,000 | 0 | 0 | 3,661,629 | 272,600 | 0 | 9,150 | 4,413,379 |
| Chief Medical Officer | ||||||||
| Troy Ignelzi | 460,000 | 0 | 0 | 3,270,515 | 266,800 | 0 | 9,150 | 4,006,465 |
| Chief Financial Officer | ||||||||
| Charmaine Lykins | 475,000 | 0 | 0 | 0 | 275,500 | 0 | 9,150 | 759,650 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Steven Paul | $11,224,103 | $13,136,960 | $8,902,241 | ↓ −1,912,857 |
| Andrew Miller | 5,774,890 | 5,722,168 | 4,662,146 | ↑ +52,722 |
| Stephen Brannan | 4,413,379 | 4,523,798 | 3,492,833 | ↓ −110,419 |
| Troy Ignelzi | 4,006,465 | 4,513,517 | 3,751,661 | ↓ −507,052 |
| Charmaine Lykins | 759,650 | 5,832,673 | — | ↓ −5,073,023 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Karuna Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper KRTX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name KRTX as a peer is temporarily unavailable — recheck shortly.
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 7,696 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 4,496 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 1,744 | 174 | 303,055 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 3,256 | 173 | 563,158 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,245 | 180 | 404,280 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 808 | 179 | 144,551 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 265 | 177 | 46,942 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 401 | 176 | 70,452 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 1,281 | 174 | 223,035 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 99 | 204 | 20,214 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 3,969 | 203 | 804,675 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,116 | 202 | 426,861 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 1,565 | 200 | 313,172 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 10,000 | 132 | 1,316,400 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,251 | 204 | 458,754 | Common | Form 4 ↗ |
| Bill Meury | Director | 2023-12-28 | D | 8,694 | 316 | 2,749,912 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2023-12-28 | D | 3,828 | 316 | 1,210,796 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 9,696 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 5,304 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 15,000 | 317 | 4,752,150 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 9,696 | 112 | 1,085,661 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 5,304 | 132 | 698,219 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 818 | 317 | 258,946 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 4,182 | 316 | 1,321,721 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 5,000 | 112 | 559,850 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-09 | D | 1,046 | 317 | 331,728 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-09 | D | 1,011 | 317 | 320,629 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-09 | D | 804 | 317 | 254,981 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-02-13 | A | 38,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-13 | A | 15,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | D | 278 | 318 | 88,404 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 27,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 4,008 | 100 | 399,678 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 27,510 | 7 | 199,998 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 4,008 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-29 | A | 47,378 | 315 | 14,932,598 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2024-03-08 | — | 1,791 | — | — | 1 insider, 1 accrual row | ||
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 3,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 100 | 319 | 31,896 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 4,900 | 318 | 1,559,817 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 1,791 | 112 | 200,538 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 3,209 | 132 | 422,433 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 17,350 | 143 | 2,476,539 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 37,813 | 218 | 8,244,368 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 12,837 | 198 | 2,546,347 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 50,000 | 230 | 11,514,000 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,362 | 321 | 2,040,930 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 4,677 | 325 | 1,517,920 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,487 | 330 | 2,140,710 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 36,117 | 330 | 11,918,610 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 22,800 | 143 | 3,254,472 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 146,900 | 218 | 32,028,607 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 135,992 | 230 | 31,316,238 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 71,121 | 310 | 22,046,088 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 15,205 | 321 | 4,877,764 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 87,494 | 321 | 28,068,075 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 449,463 | 321 | 144,187,730 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 757,045 | 323 | 244,321,133 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 136,094 | 323 | 43,952,918 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 35,877 | 330 | 11,839,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 33,882 | 330 | 11,181,060 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 10,000 | 330 | 3,300,000 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 8,550 | 330 | 2,821,500 | Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 976 | 137 | 133,527 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 25,000 | 243 | 6,083,750 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 25,000 | 226 | 5,643,500 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 2,046 | 330 | 675,180 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 13,000 | 245 | 3,186,820 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 29,937 | 138 | 4,126,815 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 8,828 | 330 | 2,913,240 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 5,000 | 330 | 1,650,000 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 63,065 | 137 | 8,627,923 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 38,688 | 330 | 12,767,040 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 19,037 | 330 | 6,282,210 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 10,342 | 330 | 3,412,860 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,696 | 161 | 1,238,363 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,100 | 138 | 981,291 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,312 | 218 | 2,248,325 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 6,562 | 198 | 1,301,638 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 3,281 | 230 | 755,549 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,158 | 330 | 2,362,140 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 14,009 | 330 | 4,622,970 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 25,100 | 143 | 3,582,774 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 73,250 | 218 | 15,970,698 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 66,900 | 198 | 13,270,284 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 70,000 | 230 | 16,119,600 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 231,992 | 321 | 74,423,034 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 11,578 | 323 | 3,736,568 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 47,817 | 327 | 15,639,984 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 15,855 | 330 | 5,232,150 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 9,412 | 330 | 3,105,960 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 13,977 | 330 | 4,612,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 161,850 | 198 | 32,104,566 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 616,703 | 314 | 193,644,742 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,025 | 330 | 2,648,250 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,372,441 | 330 | 452,905,530 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 683 | 330 | 225,390 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 32,500 | 330 | 10,725,000 | Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 16,250 | 314 | 5,102,500 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 19,893 | 323 | 6,420,068 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 25,000 | 235 | 5,886,000 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 7,696 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 4,496 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 1,744 | 174 | 303,055 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 3,256 | 173 | 563,158 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,245 | 180 | 404,280 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 808 | 179 | 144,551 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 265 | 177 | 46,942 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 401 | 176 | 70,452 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 1,281 | 174 | 223,035 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 99 | 204 | 20,214 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 3,969 | 203 | 804,675 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,116 | 202 | 426,861 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 1,565 | 200 | 313,172 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 10,000 | 132 | 1,316,400 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,251 | 204 | 458,754 | Common | Form 4 ↗ |
| Bill Meury | Director | 2023-12-28 | D | 8,694 | 316 | 2,749,912 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2023-12-28 | D | 3,828 | 316 | 1,210,796 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 9,696 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 5,304 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 15,000 | 317 | 4,752,150 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 9,696 | 112 | 1,085,661 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 5,304 | 132 | 698,219 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 818 | 317 | 258,946 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 4,182 | 316 | 1,321,721 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 5,000 | 112 | 559,850 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-09 | D | 1,046 | 317 | 331,728 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-09 | D | 1,011 | 317 | 320,629 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-09 | D | 804 | 317 | 254,981 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-02-13 | A | 38,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-13 | A | 15,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | D | 278 | 318 | 88,404 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 27,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 4,008 | 100 | 399,678 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 27,510 | 7 | 199,998 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 4,008 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-29 | A | 47,378 | 315 | 14,932,598 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 1,791 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 3,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 100 | 319 | 31,896 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 4,900 | 318 | 1,559,817 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 1,791 | 112 | 200,538 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 3,209 | 132 | 422,433 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 17,350 | 143 | 2,476,539 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 37,813 | 218 | 8,244,368 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 12,837 | 198 | 2,546,347 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 50,000 | 230 | 11,514,000 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,362 | 321 | 2,040,930 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 4,677 | 325 | 1,517,920 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,487 | 330 | 2,140,710 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 36,117 | 330 | 11,918,610 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 22,800 | 143 | 3,254,472 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 146,900 | 218 | 32,028,607 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 135,992 | 230 | 31,316,238 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 71,121 | 310 | 22,046,088 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 15,205 | 321 | 4,877,764 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 87,494 | 321 | 28,068,075 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 449,463 | 321 | 144,187,730 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 757,045 | 323 | 244,321,133 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 136,094 | 323 | 43,952,918 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 35,877 | 330 | 11,839,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 33,882 | 330 | 11,181,060 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 10,000 | 330 | 3,300,000 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 8,550 | 330 | 2,821,500 | Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 976 | 137 | 133,527 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 25,000 | 243 | 6,083,750 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 25,000 | 226 | 5,643,500 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 2,046 | 330 | 675,180 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 13,000 | 245 | 3,186,820 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 29,937 | 138 | 4,126,815 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 8,828 | 330 | 2,913,240 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 5,000 | 330 | 1,650,000 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 63,065 | 137 | 8,627,923 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 38,688 | 330 | 12,767,040 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 19,037 | 330 | 6,282,210 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 10,342 | 330 | 3,412,860 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,696 | 161 | 1,238,363 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,100 | 138 | 981,291 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,312 | 218 | 2,248,325 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 6,562 | 198 | 1,301,638 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 3,281 | 230 | 755,549 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,158 | 330 | 2,362,140 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 14,009 | 330 | 4,622,970 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 25,100 | 143 | 3,582,774 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 73,250 | 218 | 15,970,698 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 66,900 | 198 | 13,270,284 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 70,000 | 230 | 16,119,600 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 231,992 | 321 | 74,423,034 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 11,578 | 323 | 3,736,568 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 47,817 | 327 | 15,639,984 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 15,855 | 330 | 5,232,150 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 9,412 | 330 | 3,105,960 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 13,977 | 330 | 4,612,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 161,850 | 198 | 32,104,566 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 616,703 | 314 | 193,644,742 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,025 | 330 | 2,648,250 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,372,441 | 330 | 452,905,530 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 683 | 330 | 225,390 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 32,500 | 330 | 10,725,000 | Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 16,250 | 314 | 5,102,500 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 19,893 | 323 | 6,420,068 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 25,000 | 235 | 5,886,000 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Troy Ignelzi | OPTION | 2022-02-16 | — | — | 48,500 | — | $3,270,515 |
| Stephen Brannan | OPTION | 2022-02-16 | — | — | 54,300 | — | 3,661,629 |
| Andrew Miller | OPTION | 2022-02-16 | — | — | 73,250 | — | 4,939,490 |
| Steven Paul | OPTION | 2022-02-16 | — | — | 146,900 | — | 9,905,953 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Troy Ignelzi | $0 | $0 | $3,270,515 | 0.0% |
| Stephen Brannan | 0 | 0 | 3,661,629 | 0.0% |
| Andrew Miller | 0 | 0 | 4,939,490 | 0.0% |
| Steven Paul | 0 | 0 | 9,905,953 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Stephen Brannan | Option | 15,625 | 99.72 | — |
| Steven Paul | Option | 43,750 | 99.72 | — |
| Andrew Miller | Option | 37,631 | 131.64 | — |
| Stephen Brannan | Option | 28,884 | 131.64 | — |
| Troy Ignelzi | Option | 48,500 | 111.97 | — |
| Stephen Brannan | Option | 11,362 | 9.2 | — |
| Troy Ignelzi | Option | 17,187 | 99.72 | — |
| Steven Paul | Option | 146,900 | 111.97 | — |
| Steven Paul | Option | 91,040 | 131.64 | — |
| Troy Ignelzi | Option | 34,224 | 9.2 | — |
| Troy Ignelzi | Option | 29,053 | 131.64 | — |
| Andrew Miller | Option | 21,875 | 99.72 | — |
| Andrew Miller | Option | 73,250 | 111.97 | — |
| Stephen Brannan | Option | 54,300 | 111.97 | — |
| Charmaine Lykins | Option | 56,250 | 125.52 | — |
The company's compensation philosophy is performance-based, focusing on aligning the financial interests of executive officers with those of shareholders by placing a substantial portion of total compensation 'at risk' through variable pay tied to pre-set, objective financial or operating goals and stock price appreciation. The program aims to link pay to the achievement of corporate and strategic goals, promote an ownership culture through equity, and provide market-competitive compensation to attract and retain talent.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-06-20 | 20,307,726 | 10,859,879 | 413,451 | 65.16% | Passed |
| 2022 | 2022-06-15 | 21,124,063 | 5,639,878 | 414,027 | 78.93% | Passed |
| 2020 | 2020-06-15 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2023 | 2023-06-20 | 65.16%a |
| 2022 | 2022-06-15 | 78.93%b |
| 2020 | 2020-06-15 | —c |
a. Approved under the standard stated in the filing — “As a result, such "broker non-votes" and abstentions will have no effect on the voting on Proposal 2.”.
b. Approved under the standard stated in the filing — “As a result, such broker non-votes and abstentions will have no effect on the voting on Proposal 2.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 27 : 1 |
|---|---|
| CEO total compensation | $11,224,103 |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christopher J. CoughlinIndependent · Board Chair · Audit (Chair) · Compensation | $89,042 | $0 | $284,104 | — | $0 | $373,145 |
| Laurie OlsonIndependent · Audit · Nominating and Corporate Governance (Chair) | 61,000 | 0 | 284,104 | — | 0 | 345,104 |
| Atul Pande, M.DIndependent · Compensation (Chair) · Nominating and Corporate Governance | 60,500 | 0 | 284,104 | — | 0 | 344,604 |
| James Healy, M.D., Ph.DIndependent · Audit | 52,000 | 0 | 284,104 | — | 0 | 336,104 |
| Denice TorresIndependent · Compensation | 49,250 | 0 | 284,104 | — | 0 | 333,354 |
| David Wheadon, M.DIndependent · Nominating and Corporate Governance | 47,000 | 0 | 284,104 | — | 0 | 331,104 |
| Jeffrey Jonas, M.DNot independent | 42,500 | 0 | 284,104 | — | 0 | 326,604 |
| Steven Paul, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Bill MeuryEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $401,292 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $401,292 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Karuna Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Karuna Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics, Inc. | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 3 | Biohaven Pharmaceutical Holding Company Ltd. | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 4 | Mirati Therapeutics, Inc. | 2022 | David Meek | 749,423 | 6,043,885 | 4,233,427 | 438,985 | 11,937,371 |
| 5 | Cerevel Therapeutics Holdings, Inc. | 2022 | N. Anthony Coles | 642,735 | 0 | 10,085,985 | 496,706 | 11,225,426 |
| 6 | Karuna Therapeutics | 2022 | Steven Paul | 700,000 | 0 | 9,905,953 | 609,000 | 11,224,103 |
| 7 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 8 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 9 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 10 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 11 | Sage Therapeutics, Inc. | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 12 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 13 | Allakos Inc. | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 14 | Prothena Corporation plc | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 15 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 16 | Kodiak Sciences Inc. | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 17 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| — | BioXcel Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Karuna Therapeutics | 145% | Option 100 | not disclosed | Aon |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allakos Inc. | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Biohaven Pharmaceutical Holding Company Ltd. | not disclosed | not disclosed | not disclosed | Aon |
| BioXcel Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, a part of Aon plc |
| Cerevel Therapeutics Holdings, Inc. | 128.8% | Options 100 | not disclosed | Pay Governance LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Kodiak Sciences Inc. | 150% | Options 100 | not disclosed | Compensia, Inc. |
| Mirati Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon Human Capital Solutions and Alpine Rewards |
| Prothena Corporation plc | 100% | not disclosed | not disclosed | Pay Governance LLC |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Sage Therapeutics, Inc. | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| TG Therapeutics, Inc. | 131% | RSU 100 | No | Compensia, Inc. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Steven Paul | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Executive Compensation”. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694 |
| 2 | Section 01, Andrew Miller | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Executive Compensation”. As printed: 5,774,890. Filing ↗machine: r8 · c25 · span 921070–921079 |
| 3 | Section 01, Stephen Brannan | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Executive Compensation”. As printed: 4,413,379. Filing ↗machine: r11 · c25 · span 953156–953165 |
| 4 | Section 01, Troy Ignelzi | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Executive Compensation”. As printed: 4,006,465. Filing ↗machine: r5 · c25 · span 888985–888994 |
| 5 | Section 01, Charmaine Lykins | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Executive Compensation”. As printed: 759,650. Filing ↗machine: r14 · c25 · span 985148–985155 |
| 6 | Section 03, Troy Ignelzi OPTION | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r3 · c5 · span 794519–794525 |
| 7 | Section 03, Stephen Brannan OPTION | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r5 · c5 · span 800520–800526 |
| 8 | Section 03, Andrew Miller OPTION | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r4 · c5 · span 797519–797525 |
| 9 | Section 03, Steven Paul OPTION | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r2 · c5 · span 791526–791533 |
| 10 | Section 07, pay ratio | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “CEO Pay Ratio”. As printed: 27 : 1. Filing ↗ |
| 11 | Section 08, Christopher J. Coughlin | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 373,145. Filing ↗machine: span 1862829–1863168 |
| 12 | Section 08, Laurie Olson | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 345,104. Filing ↗machine: span 1884037–1884376 |
| 13 | Section 08, Atul Pande, M.D | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 344,604. Filing ↗machine: span 1891104–1891443 |
| 14 | Section 08, James Healy, M.D., Ph.D | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 336,104. Filing ↗machine: span 1869904–1870243 |
| 15 | Section 08, Denice Torres | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 333,354. Filing ↗machine: span 1898168–1898507 |
| 16 | Section 08, David Wheadon, M.D | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 331,104. Filing ↗machine: span 1905238–1905577 |
| 17 | Section 08, Jeffrey Jonas, M.D | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 326,604. Filing ↗machine: span 1876974–1877313 |
| 18 | Section 08, Steven Paul, M.D | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 08, Bill Meury | DEF 14A | 2023-04-27 | 0000950170-23-014979 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 20 | Section 02, Jason Parker Brown 2023-09-29 | Form 4 | 2023-10-03 | 0000950170-23-051666 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Jason Parker Brown 2023-09-29 | Form 4 | 2023-10-03 | 0000950170-23-051666 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Stephen Brannan 2023-10-09 | Form 4 | 2023-10-10 | 0000950170-23-052671 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Stephen Brannan 2023-10-09 | Form 4 | 2023-10-10 | 0000950170-23-052671 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Stephen Brannan 2023-10-09 | Form 4 | 2023-10-10 | 0000950170-23-052671 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Stephen Brannan 2023-10-09 | Form 4 | 2023-10-10 | 0000950170-23-052671 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Stephen Brannan 2023-10-09 | Form 4 | 2023-10-10 | 0000950170-23-052671 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Stephen Brannan 2023-10-09 | Form 4 | 2023-10-10 | 0000950170-23-052671 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Stephen Brannan 2023-11-08 | Form 4 | 2023-11-13 | 0000950170-23-063121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Stephen Brannan 2023-12-08 | Form 4 | 2023-12-12 | 0000950170-23-069766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Bill Meury 2023-12-28 | Form 4 | 2023-12-29 | 0000950170-23-073877 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, William P. Kane Jr 2023-12-28 | Form 4 | 2023-12-29 | 0000950170-23-073878 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Stephen Brannan 2024-01-08 | Form 4 | 2024-01-09 | 0000950170-24-003372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Stephen Brannan 2024-01-08 | Form 4 | 2024-01-09 | 0000950170-24-003372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Stephen Brannan 2024-01-08 | Form 4 | 2024-01-09 | 0000950170-24-003372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Stephen Brannan 2024-01-08 | Form 4 | 2024-01-09 | 0000950170-24-003372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Stephen Brannan 2024-01-08 | Form 4 | 2024-01-09 | 0000950170-24-003372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Stephen Brannan 2024-01-08 | Form 4 | 2024-01-09 | 0000950170-24-003372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Stephen Brannan 2024-01-08 | Form 4 | 2024-01-09 | 0000950170-24-003372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Stephen Brannan 2024-02-08 | Form 4 | 2024-02-12 | 0000950170-24-013959 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Stephen Brannan 2024-02-08 | Form 4 | 2024-02-12 | 0000950170-24-013959 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Stephen Brannan 2024-02-08 | Form 4 | 2024-02-12 | 0000950170-24-013959 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Stephen Brannan 2024-02-08 | Form 4 | 2024-02-12 | 0000950170-24-013959 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Stephen Brannan 2024-02-08 | Form 4 | 2024-02-12 | 0000950170-24-013959 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Stephen Brannan 2024-02-08 | Form 4 | 2024-02-12 | 0000950170-24-013959 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Stephen Brannan 2024-02-09 | Form 4 | 2024-02-12 | 0000950170-24-013959 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Andrew Miller 2024-02-09 | Form 4 | 2024-02-12 | 0000950170-24-013962 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Steven Paul 2024-02-09 | Form 4 | 2024-02-12 | 0000950170-24-013963 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Stephen Brannan 2024-02-13 | Form 4 | 2024-02-15 | 0000950170-24-015967 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Bill Meury 2024-02-13 | Form 4 | 2024-02-15 | 0000950170-24-015952 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Andrew Miller 2024-02-13 | Form 4 | 2024-02-15 | 0000950170-24-015958 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Jason Parker Brown 2024-02-13 | Form 4 | 2024-02-15 | 0000950170-24-015963 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Jason Parker Brown 2024-02-13 | Form 4 | 2024-02-15 | 0000950170-24-015963 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, William P. Kane Jr 2024-02-13 | Form 4 | 2024-02-15 | 0000950170-24-015972 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Steven Paul 2024-02-23 | Form 4 | 2024-02-26 | 0000950170-24-020397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Steven Paul 2024-02-23 | Form 4 | 2024-02-26 | 0000950170-24-020397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Steven Paul 2024-02-23 | Form 4 | 2024-02-26 | 0000950170-24-020397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Steven Paul 2024-02-23 | Form 4 | 2024-02-26 | 0000950170-24-020397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Steven Paul 2024-02-29 | Form 4 | 2024-03-04 | 0000950170-24-024999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Steven Paul 2024-03-01 | Form 4 | 2024-03-04 | 0000950170-24-024999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Steven Paul 2024-03-01 | Form 4 | 2024-03-04 | 0000950170-24-024999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Steven Paul 2024-03-01 | Form 4 | 2024-03-04 | 0000950170-24-024999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Steven Paul 2024-03-01 | Form 4 | 2024-03-04 | 0000950170-24-024999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Steven Paul 2024-03-04 | Form 4 | 2024-03-04 | 0000950170-24-024999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Steven Paul 2024-03-04 | Form 4 | 2024-03-04 | 0000950170-24-024999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Stephen Brannan 2024-03-08 | Form 4 | 2024-03-11 | 0000950170-24-029406 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Stephen Brannan 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Christopher J. Coughlin 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Christopher J. Coughlin 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Christopher J. Coughlin 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Christopher J. Coughlin 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Christopher J. Coughlin 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Christopher J. Coughlin 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Denice Torres 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013934 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Denice Torres 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013934 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Denice Torres 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013934 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Denice Torres 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013934 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Laurie Olson 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Laurie Olson 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Laurie Olson 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Laurie Olson 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, William P. Kane Jr 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, William P. Kane Jr 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, William P. Kane Jr 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, William P. Kane Jr 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Bill Meury 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Bill Meury 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Bill Meury 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Bill Meury 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Jason Parker Brown 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Andrew Miller 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Steven Paul 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013933 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, James Healy 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Jeffrey M. Jonas 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Jeffrey M. Jonas 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Jeffrey M. Jonas 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Jeffrey M. Jonas 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Jeffrey M. Jonas 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Jeffrey M. Jonas 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Jeffrey M. Jonas 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Laurie Olson 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Atul Pande 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Atul Pande 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Atul Pande 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Atul Pande 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Atul Pande 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013932 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Denice Torres 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013934 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, David E. Wheadon 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013935 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, David E. Wheadon 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013935 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, David E. Wheadon 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013935 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, David E. Wheadon 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013935 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, David E. Wheadon 2024-03-18 | Form 4 | 2024-03-18 | 0001140361-24-013935 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 06, 2023 vote | Form 8-K | 2023-06-21 | 0000950170-23-029140 | Item 5.07 · say-on-pay result. As reported: 65.16% (votes for as printed: 20,307,726). Filing ↗ |
| 185 | Section 06, 2022 vote | Form 8-K | 2022-06-21 | 0001193125-22-177034 | Item 5.07 · say-on-pay result. As reported: 78.93% (votes for as printed: 21,124,063). Filing ↗ |
| 186 | Section 06, 2020 vote | Form 8-K | 2020-06-17 | 0001193125-20-171354 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 187 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 188 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 189 | Section 09b board cost (computed) | Computed | — | — | Cash 401,292 + equity 0 + all other 0 = 401,292, summed across the director compensation table rows.machine: formula: Σ = 401,292 |
| 190 | TG Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014233 | CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. Filing ↗machine: r4 · c24 · span 404551–404561 |
| 191 | Rhythm Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 192 | Biohaven Pharmaceutical Holding Company Ltd., Section 10b CEO total | DEF 14A | 2026-03-13 | 0001935979-26-000028 | CEO total compensation as printed in Biohaven Pharmaceutical Holding Company Ltd.'s own proxy. As printed: 13,500,438. Filing ↗machine: r3 · c21 · span 423429–423439 |
| 193 | Mirati Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2023-04-06 | 0001628280-23-011004 | CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. Filing ↗machine: r2 · c45 · span 540567–540577 |
| 194 | Cerevel Therapeutics Holdings, Inc., Section 10b CEO total | DEF 14A | 2023-04-28 | 0000950170-23-015766 | CEO total compensation as printed in Cerevel Therapeutics Holdings, Inc.'s own proxy. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016 |
| 195 | Karuna Therapeutics (subject), Section 10b CEO total | DEF 14A | 2023-04-27 | 0000950170-23-014979 | CEO total compensation as printed in Karuna Therapeutics's own proxy. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694 |
| 196 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 197 | Axsome Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 198 | Intra-Cellular Therapies, Inc., Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 199 | Acadia Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 200 | Sage Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-058060 | CEO total compensation as printed in Sage Therapeutics, Inc.'s own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793 |
| 201 | Arvinas, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 202 | Allakos Inc., Section 10b CEO total | DEF 14A | 2024-04-23 | 0000950170-24-047043 | CEO total compensation as printed in Allakos Inc.'s own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107 |
| 203 | Prothena Corporation plc, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001559053-26-000012 | CEO total compensation as printed in Prothena Corporation plc's own proxy. As printed: 5,896,045. Filing ↗machine: r3 · c27 · span 627016–627025 |
| 204 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 205 | Kodiak Sciences Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170429 | CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068 |
| 206 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 207 | Section 10a, Prothena Corporation plc reciprocity | DEF 14A | — | 0001559053-26-000012 | Prothena Corporation plc's most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 208 | Section 10a, Biohaven Pharmaceutical Holding Company Ltd. reciprocity | DEF 14A | — | 0001935979-26-000028 | Biohaven Pharmaceutical Holding Company Ltd.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 209 | Section 10a, Acadia Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | Acadia Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 210 | Section 10a, Cerevel Therapeutics Holdings, Inc. reciprocity | DEF 14A | — | 0000950170-23-015766 | Cerevel Therapeutics Holdings, Inc. names Karuna Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 211 | Section 10a, Axsome Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 212 | Section 10a, Rhythm Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 213 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 214 | Section 10a, Intra-Cellular Therapies, Inc. reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 215 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 216 | Section 10a, Allakos Inc. reciprocity | DEF 14A | — | 0000950170-24-047043 | Allakos Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 217 | Section 10a, Arvinas, Inc. reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 218 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 219 | Section 10a, Kodiak Sciences Inc. reciprocity | DEF 14A | — | 0001193125-26-170429 | Kodiak Sciences Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 220 | Section 10a, Mirati Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-23-011004 | Mirati Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 221 | Section 10a, Sage Therapeutics, Inc. reciprocity | DEF 14A | — | 0000950170-25-058060 | Sage Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
| 222 | Section 10a, TG Therapeutics, Inc. reciprocity | DEF 14A | — | 0001437749-26-014233 | TG Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.